Skip to Content

RSR13 Approval Status

  • FDA approved: No
  • Brand name: RSR13
  • Generic name: efaproxiral
  • Company: Allos Therapeutics, Inc.
  • Treatment for: Brain Metastases in patients with Breast Cancer

Development Status and FDA Approval Process for RSR13

DateArticle
Jun 16, 2004Allos Therapeutics Announces New Trade Names for Efaproxiral in the U.S. and Europe
Jun  2, 2004Allos Therapeutics Receives FDA Approvable Letter for RSR13 (efaproxiral)
May  4, 2004FDA Advisory Committee Does Not Recommend Approval of RSR13 as Adjunctive Therapy for the Treatment of Brain Metastases Originating From Breast Cancer
Mar 12, 2004Allos NDA To Be Reviewed By FDA Advisory Committee
Feb  3, 2004FDA Accepts Allos New Drug Application with Priority Review for RSR13 in Brain Metastases from Breast Cancer

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide